MX2023010211A - Obicetrapib para tratamiento de demencias. - Google Patents

Obicetrapib para tratamiento de demencias.

Info

Publication number
MX2023010211A
MX2023010211A MX2023010211A MX2023010211A MX2023010211A MX 2023010211 A MX2023010211 A MX 2023010211A MX 2023010211 A MX2023010211 A MX 2023010211A MX 2023010211 A MX2023010211 A MX 2023010211A MX 2023010211 A MX2023010211 A MX 2023010211A
Authority
MX
Mexico
Prior art keywords
obicetrapib
dementias
treatment
subject
neurodegenerative disease
Prior art date
Application number
MX2023010211A
Other languages
English (en)
Inventor
Johannes Jacob Pieter Kastelein
Marc Ditmarsch
Michael Harvey Davidson
Original Assignee
Newamsterdam Pharma B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Newamsterdam Pharma B V filed Critical Newamsterdam Pharma B V
Publication of MX2023010211A publication Critical patent/MX2023010211A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Meat, Egg Or Seafood Products (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Se presentan métodos para desacelerar la progresión de una enfermedad neurodegenerativa en un sujeto quien tiene o está en riesgo de desarrollar una enfermedad neurodegenerativa. Los métodos comprenden administrar una cantidad terapéuticamente eficaz de obicetrapib o una sal farmacéuticamente aceptable del mismo al sujeto.
MX2023010211A 2021-03-05 2022-03-04 Obicetrapib para tratamiento de demencias. MX2023010211A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163157586P 2021-03-05 2021-03-05
PCT/IB2022/000098 WO2022185120A1 (en) 2021-03-05 2022-03-04 Obicetrapib for treatment of dementias

Publications (1)

Publication Number Publication Date
MX2023010211A true MX2023010211A (es) 2023-11-22

Family

ID=81327869

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023010211A MX2023010211A (es) 2021-03-05 2022-03-04 Obicetrapib para tratamiento de demencias.

Country Status (10)

Country Link
EP (2) EP4368250A2 (es)
JP (1) JP2024513155A (es)
KR (1) KR20230159457A (es)
CN (1) CN117529319A (es)
AU (1) AU2022231417A1 (es)
BR (1) BR112023017999A2 (es)
CA (1) CA3212483A1 (es)
IL (1) IL305576A (es)
MX (1) MX2023010211A (es)
WO (1) WO2022185120A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202409008A (zh) 2022-07-05 2024-03-01 荷蘭商新阿姆斯特丹製藥公司 奧比特拉(obicetrapib)鹽及彼等之製造方法與中間體

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA90269C2 (ru) * 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
JP4531027B2 (ja) * 2005-09-29 2010-08-25 田辺三菱製薬株式会社 医薬組成物
TW200808731A (en) 2006-03-30 2008-02-16 Tanabe Seiyaku Co A process for preparing tetrahydroquinoline derivatives
EP2281824A1 (en) * 2009-08-07 2011-02-09 Noscira, S.A. Furan-imidazolone derivatives, for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders
WO2012050517A1 (en) * 2010-10-14 2012-04-19 Astrazeneca Ab Imidazole substituted pyrimidine having a high gsk3 inhibiting potency as well as pan-kinase selectivity
CN112755031A (zh) * 2014-02-05 2021-05-07 狄智玛制药私人有限公司 用于治疗或预防心血管疾病的胆固醇酯转移蛋白抑制剂和含所述抑制剂的药物组合物
DK3180314T3 (da) 2014-08-12 2022-08-29 Newamsterdam Pharma B V Fremgangsmåde til fremstilling af syntetiske mellemprodukter til fremstilling af tetrahydroquinolin-derivater

Also Published As

Publication number Publication date
WO2022185120A1 (en) 2022-09-09
AU2022231417A1 (en) 2023-10-19
EP4125911A1 (en) 2023-02-08
CN117529319A (zh) 2024-02-06
IL305576A (en) 2023-10-01
JP2024513155A (ja) 2024-03-22
EP4368250A2 (en) 2024-05-15
EP4125911B1 (en) 2024-04-24
BR112023017999A2 (pt) 2023-11-14
KR20230159457A (ko) 2023-11-21
CA3212483A1 (en) 2022-09-09

Similar Documents

Publication Publication Date Title
MX2021000538A (es) Uso de sobetirome en el tratamiento de enfermedades de mielinizacion.
MX2022007276A (es) Tratamiento de la esclerosis amiotrofica lateral y enfermedades relacionadas.
EA201790406A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
NI201100147A (es) Métodos para tratar infartos agudos de miocardio y trastornos relacionados.
MX2018006247A (es) Metodos para tratar la enfermedad de alzheimer y trastornos relacionados.
EA201490163A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
MX2014011946A (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodos de uso de los mismos.
MA43828A (fr) Agents thérapeutiques pour maladies neurodégénératives
RU2014150942A (ru) Лечение побочных эффектов в виде моторных и двигательных расстройств, связанных с лечением болезни паркинсона
BR112022002609A2 (pt) Métodos de tratamento de tumores estromais gastrointestinais
TW201613591A (en) Pharmaceutical compositions comprising a DEXTROMETHORPHAN compound and QUINIDINE for the treatment of agitation in dementia
PH12021550043A1 (en) Use of riluzole prodrugs to treat alzheimer's disease
PH12020551911A1 (en) Use of riluzole oral disintigrating tablets for treating diseases
PH12021550218A1 (en) Use of riluzole oral disintigrating tablets for treating diseases
MX2023010211A (es) Obicetrapib para tratamiento de demencias.
MX2022000143A (es) Metodos novedosos.
WO2020128614A8 (en) Method for treating interstital lung disease
RU2016102092A (ru) Тауроурсодезоксихолевая кислота (tudca) для применения в лечении нейродегенеративных нарушений
PH12020550722A1 (en) Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye
EA201170970A1 (ru) Применение деферипрона для лечения и предупреждения заболеваний глаз, связанных с железом
CL2021003303A1 (es) Tratamiento para sinucleinopatías.
EA201990559A1 (ru) Комбинированная терапия
MX2021014093A (es) Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson.
EA202193190A1 (ru) Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов
EA202090416A1 (ru) Способы лечения симптомов гастропареза с использованием велусетрага